Pfizer's Oral GLP-1 Program: What Went Wrong, and What's Next
Pfizer discontinued danuglipron, one of its oral GLP-1 candidates, after tolerability and liver-safety signals emerged in trials. Here's what that means for its broader pipeline.
By the GLP Semaglutide editorial team · Last updated April 5, 2026
Pfizer's oral GLP-1 candidate program faced high-profile setbacks, including discontinuing a lead candidate after trial data raised tolerability and safety concerns, a reminder that late-stage drug development carries real failure risk even for well-funded programs.
Why oral small molecules are harder
Oral small-molecule GLP-1 candidates (distinct from peptide-based oral drugs like Rybelsus) face their own formulation and dosing challenges, and Pfizer's setbacks have been cited industry-wide as a data point in an actively competitive and technically difficult area of drug development.
Pipeline status changes fast
Companies frequently reprioritize pipeline candidates based on trial results; checking a company's current investor communications is the most reliable way to know which programs remain active.
Primary sources